v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 225,479 $ 349,500
General and administrative 213,974 143,770
General and administrative affiliates 1,493,600 21,872
Total operating expenses 1,933,053 515,142
Loss from operations (1,933,053) (515,142)
Other expenses:    
Change in fair value (“FV”) of derivative (73,136) (804,752)
Interest expense (35,729) (31,157)
Interest expense affiliate (24,963) (733)
Amortization of Intellectual Property (2,108) (1,851)
Total other expenses (135,936) (838,493)
Net loss before provision for income taxes (2,068,989) (1,353,635)
Provision for income taxes
Net loss (2,068,989) (1,353,635)
Net loss attributable to the non-controlling interest
NET LOSS ATTRIBUTABLE TO BIOXYTRAN $ (2,068,989) $ (1,353,635)
Loss per common share, basic $ (0.02) $ (0.02)
Loss per common share, diluted $ (0.02) $ (0.02)
Weighted average number of common shares outstanding, basic 112,283,387 88,839,723
Weighted average number of common shares outstanding, diluted 112,283,387 88,839,723